• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    How An Ancient Medicine Is Taking On The $16 Trillion Pharmaceutical Industry

    12/3/20 9:00:00 AM ET
    $TAP
    $MO
    $JNJ
    $HEXO
    Beverages (Production/Distribution)
    Consumer Staples
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TAP alert in real time by email

    LONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical.   Mentioned in today's commentary includes:  Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CURLF).

    Why? Soon, global spending on mental healthcare will hit $16 trillion, and researchers say it has huge implications for people with…

    • Depression and anxiety
    • PTSD
    • Addiction
    • And many other disabling diseases…

    And one company, Lobe Sciences (LOBE; GTSIF), is on the cutting edge of this new 'transformational medicine."

    Breakthrough Therapy Backed By Science

    Working in partnership with the University of Miami, Lobe Sciences is on the leading edge of this biotech breakthrough.

    Lobe points to a Johns Hopkins study of the efficacy of these compounds for treatment of depression and anxiety (a market to grow to $18.9 billion by 2026) that concluded that psilocybin eased depression and anxiety in patients with life-threatening cancer. 

    But that was back in 2016. Since, a collection of new studies has taken this far beyond cancer patients and into the general population suffering from widespread depression, anxiety and PTSD. According to Alan Davis, the author of one such 2020 study and a faculty member at Johns Hopkins University and Ohio State University, psilocybin's effect was "more than four times greater". 

    Smart Money Is Going All In

    Tim Ferriss, angel investor extraordinaire funded Johns Hopkins' psychedelic research center with over $2 million. Ferriss says this is the world's proof-of-concept demonstration--the Silicon Valley of psychedelics. 

    Brad Loncar, lead biotech investor at Loncar Investments, pinpointed the "ultimate sign for investors" when big pharma got its first approval for a psychedelic-based anti-depressant in the Spring of 2019. 

    Multi-billionaire and PayPal co-founder Peter Thiel has put big money into this industry. Mike Novogratz has also been selling the psychedelic space for years, lauding its massive investment merits.

    Johnson & Johnson has been pouring money into R&D for years. When the FDA approved SPRAVATO ketamine-like nasal spray as an antidepressant in 2019, it was a signal to investors that a new side of biotech was about to explode. 

    And Lobe is close to a transformational PTSD development, too.  Among four others, it boasts a patent pending for a nasal mist transducer device that aims to offer a completely transformational approach to PTSD treatment. Development is already under way and the next news to come out may not just be transformational for PTSD—but for the company, as well.

    The Multi-Billion Mental Health Market

    As of 2020, more than 264 million people of all ages suffer from depression, according to the World Health Organization. Additionally, 1 in 13 people will develop PTSD at some point in their life. During the global pandemic… 1 in 20 women… and 1 in 50 men were newly diagnosed. Depression is now the No. 1 cause of disability in the world. 

    Considering many other mental disorders that psychedelic researchers are working to address, this could be a massive market opportunity. The functional mushroom market is expected to be worth more than $34 billion by 2024, according to data from Modor Intelligence. And Lobe Sciences (LOBE; GTSIF) is working hard to carve out its own piece of this market. Lobe already has five provisional patent applications on its therapy and methods... and the company's future looks bright.

    The 'Brain Science' Boom

    Just over the past year, Denver, Oakland, Santa Cruz, Ann Arbor, Oregon and Washington DC decriminalized psilocybin. The therapeutic potential of psychedelic drugs to treat the profound distress of Western society is becoming undeniable. Even the FDA thinks so.

    Similar research has been shown to be 80% effective... compared to 20%-30% for big pharma treatments. More studies will be published soon… building on this base of research.

    Surrounded by a patent moat and armed with revolutionary tech, Lobe Sciences (LOBE; GTSIF) is perfectly positioned to take advantage of the 2021's transformational science trend.

    The Same Pattern Has Already Occurred In The Cannabis Boom

    Constellation Brands (STZ), a beverage conglomerate with a stake in everything from Corona to Modelo, shook up the pot world in 2017 when it invested $191 million for a 9.9% stake in Canopy Growth, and followed it up a year later sinking an additional $4 billion into Canopy Growth Corp.

    And earlier this year, Constellation raised its stake in the promising cannabis giant once again, investing another $174 million into Canopy, raising its stake to 55.8%. David Klein, CEO of Canopy Growth, noted "This additional investment validates the work our team has done since attracting the initial investment in 2017. It also strengthens our ability to pursue the immense market and product opportunities available to Canopy in Canada, the US and other key global markets." 

    Molson Coors (TAP) is another iconic multi-national beer company, with brands that are recognizable across the United States and Canada. Not to be left behind in the marijuana boom, Molson Coors is also developing a line of non-alcoholic cannabis-based beverages with its partner, the HEXO Corporation.

    In August of this year, Molson Coors finally unveiled its cannabis drinks in its joint venture with HEXO. The lineup includes five new beverages containing CBD and THC. CEO Scott Cooper, CEO of Truss Beverage, the product of the joint venture, noted, "We're thrilled to be introducing Canadians to new beverage options and leading the cannabis beverage category with our variety of products."

    Big Tobacco is all in on this market, as well. Altria (MO) got into the marijuana game in a big way in 2018, investing $1.8 billion in the Canadian pot firm Cronos Group. The deal sent Cronos stock into the stratosphere and positioned Altria as one of the first mainstream tobacco firms to take a hard line in support of the cannabis market.

    Year-to-date, Altria has seen its share price fall by 18%. But that doesn't mean it's not still a good buy. As the cannabis industry continues to gain traction, Altria offers potential shareholders something many other stocks in the industry don't: dividends. Altria has maintained its high-dividend yield for years now, and though its share price has slipped slightly this year, its dividend payouts are still appealing.

    GW Pharmaceuticals (GWPH) got into the cannabis game through a major industry milestone. Back in 2018, GW Pharma received approval for its cannabis-based drug Epidiolex from the Federal Drug Administration. It was the first FDA approved drug based on cannabis for the American market…and GW Pharma's stock enjoyed a huge boost at the news.

    GW had a stellar third-quarter, reporting a yearly growth in revenue of 50% due in part to the sales of Epidiolex. Justin Gover, GW's CEO explained, "We are pleased to report strong revenue growth in the 3rd quarter despite the challenges presented by COVID-19. Epidiolex meets a serious unmet need within the field of epilepsy and we expect the product to demonstrate continued strong growth in the months and years ahead," adding, "The recent expanded indication for the treatment of seizures associated with TSC has been very well received by patients, clinicians and payers."

    Curaleaf Holdings (CURLF) is an up-and-coming U.S. cannabis company with big plans for vertical integration. The multi-faceted company has its hands in all levels of the cannabis game, where it cultivates and manufactures a wide range of products, operates dispensaries, and much more.

    The Massachusetts-based company has seen significant growth since it went public in what the Motley Fool called "the largest cannabis debut in history." And it's lived up to the hype. Curaleaf has had a stellar year, with its stock price bouncing from a low of $3.16 back in March to an all-time high of $10.88 at the time of writing.

    IMPORTANT NOTICE AND DISCLAIMER

    PAID ADVERTISEMENT. This article is a paid advertisement. GlobalInvestmentDaily.com and its owners, managers, employees, and assigns (collectively "the Publisher") is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Lobe Sciences to conduct investor awareness advertising and marketing. Lobe paid the Publisher to produce and disseminate five similar articles and additional banner ads at a rate of sixty thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased. 

    Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.

    This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company's SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher's knowledge, as confirmed by Lobe) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

    SHARE OWNERSHIP. The Publisher owns shares and/or stock options of the featured companies and therefore has an additional incentive to see the featured companies' stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

    FORWARD LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies' actual results of operations. Factors that could cause actual results to differ include, but are not limited to, changing governmental laws and policies impacting the company's business including the legality of Psilocybin and other psychedelics, the ability of the company to exercise or sell its option to acquire shares of Cowlitz County Cannabis Cultivation or otherwise monetize its interest in Cowlitz, the degree of success with research and development of the company's medicines and devices, the success of clinical trials, governmental approval or clearance of the company's medicines and devices, the size and growth of the market for the companies' products and services, the ability of management to execute its business plan, the continuity of management, the companies' ability to fund its capital requirements in the near term and long term, pricing pressures, etc. 

    INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

    TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://GlobalInvestmentDaily.com/Terms-of-Use. If you do not agree to the Terms of Use http://GlobalInvestmentDaily.com/Terms-of-Use, please contact GlobalInvestmentDaily.com to discontinue receiving future communications.

    INTELLECTUAL PROPERTY. GlobalInvestmentDaily.com is the Publisher's trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

    DISCLAIMER:  GlobalInvestmentDaily.com is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with GlobalInvestmentDaily.com or any company mentioned herein.  The commentary, views and opinions expressed in this release by GlobalInvestmentDaily.com are solely those of GlobalInvestmentDaily.com and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

    Contact Information:

    Media Contact
    e-mail:  [email protected] 
    U.S. Phone: +1(954)345-0611

    SOURCE GlobalInvestmentDaily.com

    Get the next $TAP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TAP
    $MO
    $JNJ
    $HEXO

    CompanyDatePrice TargetRatingAnalyst
    Altria Group Inc.
    $MO
    7/2/2025$59.00Sell → Neutral
    UBS
    Molson Coors Beverage Company
    $TAP
    6/27/2025$50.00Buy → Neutral
    BofA Securities
    Constellation Brands Inc.
    $STZ
    6/25/2025$215.00 → $195.00Buy
    Needham
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Constellation Brands Inc.
    $STZ
    5/7/2025$215.00Hold → Buy
    Truist
    Molson Coors Beverage Company
    $TAP
    4/2/2025$86.90Buy
    Berenberg
    Altria Group Inc.
    $MO
    4/1/2025Buy → Hold
    Deutsche Bank
    Constellation Brands Inc.
    $STZ
    3/27/2025$240.00 → $215.00Buy
    Needham
    More analyst ratings

    $TAP
    $MO
    $JNJ
    $HEXO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Constellation Brands Inc.

      10-Q - CONSTELLATION BRANDS, INC. (0000016918) (Filer)

      7/2/25 2:00:13 PM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples
    • Constellation Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CONSTELLATION BRANDS, INC. (0000016918) (Filer)

      7/1/25 4:12:15 PM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples
    • Molson Coors Beverage Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - MOLSON COORS BEVERAGE CO (0000024545) (Filer)

      6/27/25 4:30:46 PM ET
      $TAP
      Beverages (Production/Distribution)
      Consumer Staples

    $TAP
    $MO
    $JNJ
    $HEXO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Winnefeld James A Jr bought $10,800 worth of Class B Common Stock (200 units at $54.00), increasing direct ownership by 1% to 19,166 units (SEC Form 4)

      4 - MOLSON COORS BEVERAGE CO (0000024545) (Issuer)

      5/9/25 4:30:11 PM ET
      $TAP
      Beverages (Production/Distribution)
      Consumer Staples
    • Director Giles William T bought $186,390 worth of shares (1,000 units at $186.39), increasing direct ownership by 216% to 1,463 units (SEC Form 4)

      4 - CONSTELLATION BRANDS, INC. (0000016918) (Issuer)

      1/21/25 8:31:14 AM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAP
    $MO
    $JNJ
    $HEXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Altria upgraded by UBS with a new price target

      UBS upgraded Altria from Sell to Neutral and set a new price target of $59.00

      7/2/25 7:43:20 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Molson Coors Brewing downgraded by BofA Securities with a new price target

      BofA Securities downgraded Molson Coors Brewing from Buy to Neutral and set a new price target of $50.00

      6/27/25 7:46:40 AM ET
      $TAP
      Beverages (Production/Distribution)
      Consumer Staples
    • Needham reiterated coverage on Constellation Brands with a new price target

      Needham reiterated coverage of Constellation Brands with a rating of Buy and set a new price target of $195.00 from $215.00 previously

      6/25/25 7:41:36 AM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples

    $TAP
    $MO
    $JNJ
    $HEXO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Constellation Brands Reports First Quarter Fiscal 2026 Financial Results

      ROCHESTER, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ), a leading beverage alcohol company, reported today its first quarter fiscal 2026 financial results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Chief Financial Officer, Garth Hankinson, on Wednesday, July 2, 2025 at 10:30 a.m. ET. Visit ir.cbrands.com to locate information for joining the conference call, or a live, listen-only webcast of the conference call. ABOUT CONSTELLATION BRANDSConstellation Brands (NYSE:STZ) is a leading international producer and marketer of beer, wine, and spirits with operations

      7/1/25 4:05:49 PM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples
    • Vicarious Surgical Announces Election of New Directors

      Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company's 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious Surgical Board of Directors effective as of the Annual Meeting. "On behalf of the board, I am thrilled to welcome Fuad and Joseph to the Vicarious team. Their decades of experience and insight will be instrumental as we continue our advance towards our clinical trial and th

      6/30/25 6:45:00 AM ET
      $GSAT
      $IRIX
      $JNJ
      $MITK
      Telecommunications Equipment
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

      The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG IMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year for the broadest population of individuals living with gMG, including anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older SPRING HOUSE, Pa., June 23, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ (nipocalimab-aahu) versu

      6/23/25 7:32:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAP
    $MO
    $JNJ
    $HEXO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAP
    $MO
    $JNJ
    $HEXO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Herington Charles M was granted 287 units of Class B Common Stock, increasing direct ownership by 0.48% to 60,625 units (SEC Form 4)

      4 - MOLSON COORS BEVERAGE CO (0000024545) (Issuer)

      7/2/25 4:25:11 PM ET
      $TAP
      Beverages (Production/Distribution)
      Consumer Staples
    • Director Cocks Christian P was granted 315 units of Class B Common Stock, increasing direct ownership by 10% to 3,337 units (SEC Form 4)

      4 - MOLSON COORS BEVERAGE CO (0000024545) (Issuer)

      7/2/25 4:25:00 PM ET
      $TAP
      Beverages (Production/Distribution)
      Consumer Staples
    • Director Yanofsky Theresa sold $12,823 worth of shares (10,425 units at $1.23), decreasing direct ownership by 11% to 84,360 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      7/2/25 4:16:20 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $TAP
    $MO
    $JNJ
    $HEXO
    Financials

    Live finance-specific insights

    See more
    • Constellation Brands Reports First Quarter Fiscal 2026 Financial Results

      ROCHESTER, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ), a leading beverage alcohol company, reported today its first quarter fiscal 2026 financial results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Chief Financial Officer, Garth Hankinson, on Wednesday, July 2, 2025 at 10:30 a.m. ET. Visit ir.cbrands.com to locate information for joining the conference call, or a live, listen-only webcast of the conference call. ABOUT CONSTELLATION BRANDSConstellation Brands (NYSE:STZ) is a leading international producer and marketer of beer, wine, and spirits with operations

      7/1/25 4:05:49 PM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples
    • Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

      Canada cannabis revenue increased 4% in Q4 FY2025 year-over-year, led by 13% growth in Canada medical cannabis Reduced total debt by $293 million or 49% during FY2025 Refined strategy, focus and organizational structure expected to accelerate growth in global medical cannabis and improve commercial execution in Canada adult-use cannabis Additional cost reduction initiatives identified and initiated in Q4 FY2025 are expected to deliver at least $20 million in annualized savings over the next 12-18 months Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") a

      5/30/25 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Constellation Brands to Report First Quarter 2026 Financial Results on July 1, 2025 After Market Close and Host Conference Call on July 2, 2025 at 10:30 AM ET

      ROCHESTER, N.Y., May 29, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ), a leading beverage alcohol company, announced today it will report financial results for its first quarter ending May 31, 2025, on Tuesday, July 1, 2025, after the close of the U.S. markets by posting the earnings release and financial tables, as well as other supporting materials, on the company's investor relations website at ir.cbrands.com. A live conference call for analysts to discuss the company's financial results, operating performance, strategic business initiatives, and outlook for the future with President and Chief Executive Officer, Bill Newlands, and Executive Vice President and Chief Fin

      5/29/25 4:30:13 PM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples

    $TAP
    $MO
    $JNJ
    $HEXO
    Leadership Updates

    Live Leadership Updates

    See more
    • Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

      Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

      6/10/25 4:51:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Constellation Brands Announces Industry Veteran Paula Erickson as Incoming Chief Human Resources Officer

      ROCHESTER, N.Y., April 14, 2025 (GLOBE NEWSWIRE) -- Constellation Brands (NYSE:STZ), a leading beverage alcohol company, announced today that Paula Erickson will join the company and assume the role of Executive Vice President and Chief Human Resources Officer, effective April 21, 2025. Erickson will join the company's Executive Management Committee and have oversight responsibility for all aspects of Constellation's HR business partnership, global talent initiatives, HR operations, and global total rewards programs. The company and Kris Carey, Constellation's current Executive Vice President and Chief Human Resources Officer, have mutually agreed that Carey will step down from her role a

      4/14/25 4:35:00 PM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples
    • Molson Coors Nominates Chris Cocks as an Independent Director to Join Its Board of Directors

      The Molson Coors Beverage Company ("Molson Coors" or "the company") (NYSE:TAP, TAP.A)) Board of Directors today announced that Christian "Chris" Cocks has been nominated as an independent Class B director for election at the company's Annual Meeting of Stockholders on May 14, 2025. Cocks is a seasoned consumer goods executive who serves as Chief Executive Officer of Hasbro, Inc (NASDAQ:HAS), a leading games, IP and toy company. "With his background evolving a historic business in the consumer goods industry and a track record of driving commercial and operational success, we believe Chris will bring valuable experience and a great voice to our Board. We are very happy to nominate Chris for

      4/2/25 9:00:00 AM ET
      $HAS
      $MSFT
      $TAP
      Recreational Games/Products/Toys
      Consumer Discretionary
      Computer Software: Prepackaged Software
      Technology

    $TAP
    $MO
    $JNJ
    $HEXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Constellation Brands Inc.

      SC 13G - CONSTELLATION BRANDS, INC. (0000016918) (Subject)

      11/13/24 12:49:26 PM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples
    • SEC Form SC 13G filed by Constellation Brands Inc.

      SC 13G - CONSTELLATION BRANDS, INC. (0000016918) (Subject)

      11/13/24 10:22:19 AM ET
      $STZ
      Beverages (Production/Distribution)
      Consumer Staples
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      4/19/24 5:00:49 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care